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ABSTRACT 
This research work explores the surface chemistry and drug-polymer interaction in the 
manufactured controlled release micro-particles. Isoniazid (INH) was used as a model anti-
tubercular drug while Eudragit® S100 (S100), Eudragit®L100-55 based co-processed Acryl 
EZE (EZE) and Ethylcellulose ECN10 (ECN10) were used as polymeric carriers. INH 
containing micro-particles were prepared using a mini spray dryer B-290 (Buchi, 
Switzerland). The drug polymer ratios were optimized at 1:1 and 1:3 to evaluate the effect of 
polymers on the release of the drug from the micro-particles. Solid state characterization via 
SEM and particle size analysis of the manufactured micro-particles showed densely 
aggregated spherical particles with a mean diameter less than 10 µm. The advanced surface 
analysis via EDS revealed a homogenous drug distribution on the spray dried micro-particles. 
The physico-chemical characterization carried out by using DSC and XRPD showed an 
increase in the amorphicity of the drug during the spray drying process while the chemical 
elemental analysis via XPS revealed a strong intermolecular interaction between the amine 
group of the drug and the carboxyl group of the polymers. As expected, the in vitro 
dissolution study showed a slow release pattern for the highly water soluble drug INH in 
acidic media (pH 1.2) for the first 2 h followed by a burst release upon changing the pH to 
6.8. It was concluded that emerging spray drying processing can be used as a valuable tool to 
encapsulate drug for controlled release dosage forms by means of facilitating a possible 
drug/polymer interaction as outlined by novel XPS analysis.  
Keywords: Microencapsulation, spray drying, controlled release, amorphous, crystalline, 
micro-particles. 
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ABBREVIATIONS 
ANOVA  Analysis of variation 
BE   Binding energy 
DL  Drug loading 
DSC   Differential scanning calorimetry 
ECN10 Ethyl Cellulose N10 
EDS  Energy dispersive X-ray 
EE  Encapsulation efficiency 
EZE  Eudragit L100-55 (Acryl EZE) 
HPLC  High performance liquid chromatography 
INH   Isoniazid 
S100   Eudragit S100 
SEM  Scanning electron microscopy 
SSA  Specific surface area 
XPS   X-ray photoelectron spectroscopy 
XRPD  X-ray powder diffraction 
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1. Introduction 
‘Microencapsulation’ via spray drying process is referred to a technique in which a 
drug in the form of a solid or liquid is encapsulated in a biocompatible and/or biodegradable 
polymeric matrix or pharmaceutically acceptable excipients [1]. Generally, by means of this 
process, the produced particles are with a diameter in the range of 1 to 1000 micrometers [1]. 
Microencapsulation technique has various pharmaceutical applications such as preparation of 
sustained or prolonged release medications, single layer tablet containing chemically 
incompatible ingredients and new formulation concepts for creams, aerosols, plasters, 
surgical dressings, injectable [2-5]. In the case of drugs that are poorly water soluble, 
microencapsulation process is carried out to achieve its increased dissolution rate with a fast 
onset of action [1, 5].
 
In recent years, microencapsulation process using spray drying 
technique has become quite popular due to its industrial adaptability and ease of scale up 
process meeting the regulatory requirements [1-5]. 
Spray drying is, in general term, the transformation of feed (solution, suspension or 
emulsion) from a fluid state into a dried particulate form by means of spraying the feeding 
solutions into a hot drying medium (cyclone). Spray drying is a unique process whereby the 
final product complies with the standards concerning particle size, particle size distribution, 
particle shape, moisture content and bulk density in a single step operation [1, 3, 5, 6-10]. 
Due to rapid solvent evaporation, spray drying is widely used in the drying of foodstuffs, 
pharmaceuticals, ceramics and many other substances. The most important aspect of spray 
drying is the automization of suspension into hot drying medium (usually air). The formation 
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of a fine spray due to automization is the most important factor to gain economic production 
of top quality products, by maintaining optimum conditions for evaporation [1, 6-12].
 
Controlled release drug delivery systems are aimed at achieving more predictable 
bioavailability of drugs and help in optimizing pharmaco-therapies. As compared to 
conventional dosage forms, these systems provide improved efficacy, reduced side effects 
and avoid issue with the patient compliances [2-4]. Out of all dosage forms such as tablets or 
capsules, microparticles have significant advantages such as protection of drug from the 
gastrointestinal tract by administrating through intramuscular or subcutaneous route, ease of 
administration, target specific drug delivery and no need for surgery to remove empty 
remnants [1, 2, 5].
 
Polymers can be used for the purpose of prolonging the release and in turn 
bioavailability by encapsulating the active ingredient in the polymeric matrix or shell. 
Various polymers such as Eudragit polymers, cellulose derivatives and some natural 
polymers have been successfully used in the preparation of delivery systems by spray drying. 
The success of the process depends on a number of factors such as the type of feed, the 
degree of core material encapsulation and the drug/polymer ratio [13, 14]. 
Isoniazid (INH) is a first line antitubercular drug used for the prophylaxis and therapy 
of tuberculosis caused by mycobacterium tuberculosis. The most probable mechanism of 
action of isoniazid is the inhibition of synthesis of mycolic acids which is a unique 
component of mycobacterium cell wall [15, 16]. Due to its pharmacokinetics and 
pharmacological properties, controlled release dosage forms of INH are prepared so that it 
would maximize therapeutic efficacy, reduce dosing intervals and dose related adverse effects 
[16]. INH is soluble in water (~14% at 25ºC, ~26% at 40ºC), with a pKa value of about 1.82 
and Log P 0.64, LD50 100 mg/kg (Human, oral) [16, 17].
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The aim of this study was to optimize and prepare INH loaded microparticles by 
means of spray drying techniques. For the first time, an EDS and XPS were combined to 
study the surface chemistry of the spray dried particles. The novelty of this reported study lies 
on the exploitation of novel EDS and XPS techniques to analyse the surface of the 
manufactured micro-particles and outline chemical interactions between the drug and 
polymers, respectively. Organic dispersions of either Eudragit S100 and Acryl EZE or ethyl 
cellulose derivatives with various drug/polymer ratios were evaluated to develop controlled 
release drug delivery systems of INH. 
2. Materials and Method 
2.1 Materials 
Isoniazid (INH) was purchased from Sigma Aldrich (Gillingham, UK). The polymers 
Ethyl Cellulose N10 (ECN10) was kindly donated by Harkeulus (Germany). Eudragit S100 
(S100) and Eudragit L100-55 based co-processed polymer Acryl-EZE (EZE) was kindly 
provided by Evonik Industries (Germany) and Colorcon Ltd (Dartford, UK), respectively. 
Absolute ethanol and other solvents for HPLC were of laboratory/pharmaceutical grade and 
obtained from Fisher scientific (UK).  
2.2 Spray drying process 
The microencapsulation process was performed in a B-290 mini spray dryer (Buchi, 
Basel, Switzerland). Various drug/polymer binary mixtures (1:1 and 1:3) were dissolved in 
ethanol (100 mL) as shown in Table 1. The processing parameters for all spray drying 
processes are also summarized in Table 1. Briefly, the inlet temperature was set at 100
o
C 
while the outlet at 60
o
C, the aspirator at 90% with a feed solution rate of 13-15%. The 
encapsulation yield was also calculated as the ratio of the mass of the microencapsulated 
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particles obtained during the process to the mass of the initial substances added (drug and 
polymer) 
Bulk and tap densities of the spray dried powder were also measured by taking about 
1 g of sample and placing it in a 10 mL measuring cylinder. The initial reading was taken as 
volume.  The powder in the cylinder was tapped 100 times onto a rubber mat with the help of 
a Tap Machine. This process was repeated 3 times. The final reading of the cylinder was then 
recorded and the tap density was calculated. 
The entrapment efficiency and drug loading of INH in various formulations were 
determined according to the following procedure: approximately 20 mg of the spray dried 
INH loaded microparticles was weighted and dispersed into 10 mL of phosphate buffer 
solution (pH 7.2). The mixture was continuously stirred with magnetic stirrer for 24 h 
followed by a sonication at room temperature for 30 min. The solution was then centrifuged 
at 7000 rpm for 15 min (Sorval RC6 Plus) and the supernatant was collected via the filtration 
of the solutions using 45 μm pore membrane. The amount of drug encapsulated was 
determined by determining by HPLC as per the method described below in section 2.9. The 
entrapment efficiency and the drug loading was evaluated via using the following equations 
(Eqs. 1 and 2):  
)2(100(%)
)1(100(%)


LoadingDruglTheoritica
LoadingDrugActual
EfficiencyionEncapsulat
clesMicropartiLoadedDrugofMass
DrugofMassCalculated
LoadingDrug
 
 
2.3 Particle size analysis 
The particle size distributions of all spray dried powders were determined using a 
Mastersizer 2000 laser diffraction instrument (Malvern Instruments, UK) with a dry powder 
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sample dispersion accessory (Scirocco 2000). The pressure was set at 2 bars and a vibration 
feed rate of 50%. All samples were run in triplicate. Mastersizer 2000 software was used for 
all data evaluation and interpretations as well as to calculate the d(50) which is the geometric 
median particle size and the d(10) and d(90) which are the particle diameters at 10% and 90% 
of the cumulative volume distribution, respectively. The span referred to the width of the 
distribution relative to the d(50) was calculated using the following equation (Eq. 3). 
)3(
][
)50(
)10()90(
d
dd
Span

  
2.4 Scanning Electron Microscopy (SEM)/ EDS analysis 
Micrographs of pure drugs and spray dried powders were obtained by a scanning 
electron microscopy using a JEOL JSM-5310LV machine (JEOL, Tokyo, Japan) at 15kV 
accelerating voltage, 20 mm working distance, spot size 14, secondary electron detector. 
Elemental assays and mapping were also undertaken using an AZtec Energy Dispersive X-
ray microanalysis system with 50 mm
2
 X-Max detector (EDS) (Oxford Instruments, UK). For 
the purpose of the analysis, all samples were placed on double sided adhesive carbon tapes 
stuck on aluminium stubs. All samples were then coated with a thin layer of carbon by using 
an Edwards 306 high vacuum carbon evaporator prior to each analysis.  
2.5 X-Ray Powder Diffraction (XRPD) 
For XRPD studies a Bruker D-8 Advance (Germany) system was used. The 
experiment was carried out at an angle of 2-40 2-theta values. The sample was rotated at 15 
rpm and the exit slit used was 0.2 mm. The opening angle was 3
0
. The generator condition 
was set at 40 kv and 40 mA. The counting time was 0.1 seconds per step. Lynex Eye 
controller was used. 
2.6 Differential Scanning colorimetry 
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The solid state of the pure drug, polymers and the spray dried powders was studied 
using a differential scanning colorimetry (DSC) G823e machine (Mettler Toledo, USA). 
Approximately, 1-2 mg of each sample were loaded in aluminum crucibles and sealed under 
crucible press and then the lid was pierced. The crucibles were placed in DSC and the 
samples were heated from 25
o
C to 250
o
C with a heating rate of 10
o
C/min under nitrogen. 
STARe thermal analysis software was used for data analysis. 
2.7 X-ray photoelectron spectroscopy (XPS) 
The XPS was performed to analyze the first layer atomic structure of the formulations 
via a Kratos Axis Ultra-DLD using a monochromatic Al Kα X-ray source (120 W) and an 
analyzer pass energy of 160 eV (survey scans) or 20 eV (high resolution scans). The 
operating pressure during analysis was optimized at 1×10
-9
 Torr.  The C (1s) signal at 285.0 
eV was used as a reference signal for all data and was attributable to unsaturated C-C/C-H 
bonds. CasaXPS
TM
 (Version 2.3.15) software was used for the quantification and curve 
fitting of all formulations run in the XPS analysis. 
2.8 Dissolution studies 
The dissolution studies were performed using Varian 705 DS. The temperature of the 
dissolution bath was maintained at 37
o
C and the stirring rate at 100 rpm. The dissolution 
medium used was 750 ml 0.1 N HCl solution of pH 1.2 for first two hours. The pH was then 
changed to 6.8 by using 150 ml phosphate buffer after 2 h. The spray dried samples of about 
100 mg equivalent of INH was used in each vessel. About 2-3 ml samples were withdrawn at 
an interval of 0.5, 1, 2, 3, 5 and 12 h and filtered prior to collect them in airtight glass vials. 
All samples were run in triplicates (n=3). 
2.9 High Performance Liquid Chromatography (HPLC) 
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The released INH amount was determined by using HPLC 1200 series (Aligent 
Technologies) and detected at 266 nm using a variable wavelength detector. The column used 
was HICHROM H50DS 3801 and the mobile phase methanol: water (60:40). The flow rate 
was maintained at 1.5 ml/min. various standard solution ranging 10-50 µm/ml were used to 
plot a calibration curve and calculated the drug release profile of INH.  
2.10 Release mechanism 
Zero order kinetics, first order kinetics, Hixson–Crowell, Higuchi and Korsmeyer–Peppas 
models were used for the analysis of the dissolution mechanism taking the rate constant 
obtained from these models as an apparent rate constant. The drug release patterns were 
analysed by release kinetics theories using a software suite DDSolver [18]. 
2.11 Statistical analysis 
The samples were compared with the reference (control) by an analysis of variance 
(ANOVA) test. The Microsoft Excel (MS 2013, USA) software was used to perform all 
statistical analyses. The P-value < 0.05 was considered as significant. All the results are 
expressed as mean ± standard deviation. 
3. Results and Discussion 
3.1 Spray drying processing 
Various parameters used to manufacture microencapsulated particles of 
isoniazid/polymers using the spray drying processing as well as the drug loading and 
encapsulation efficiency are summarized in Table 1. All drug and polymers used in this study 
were polar in nature and depicted in Figure 1. The difference in the yield was observed in the 
case of different polymers and formulations and some portion of the product was lost due to 
either the exhaust gas in the cyclone or some product being adhered to the cyclone. The 
highest yield was obtained in the case of ethyl cellulose derivatives (EC 10) with different 
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drug/polymer ratios. As can be seen in Table 1, the drug entrapment efficiency (%)  varies 
from 81-94.4 % which are relatively high in regards with a theorical drug loading of 25% 
w/w (actual drug loading 22.8-23.6% w/w) and 50% w/w (actual drug loading 40.5-45.1 % 
w/w). Interestingly, there was not that significant diffenerce observed in the values of actual 
drug loading and the entrapment efficiency of the drug between various polymers (with the 
same ratios). The high entrapment efficiency reflects the optimized process and most 
importantly the drug polymer miscibility/interactions. It can also be claimed that the 
optimized process and the formulation compositions can be utilized to develop novel 
formulations without compromising the high drug entrapment/encapsulation efficiency.  
Generally, it is expected that a high drying or inlet temperature will result in a faster 
drying rate leading to a higher productivity of the spray dried powders. Since the drying 
temperature used in this study was relatively high (100
o
C) in the presence of organic 
solvents, the percentage yield of all formulations was satisfactorily above the average (50-
60%) that typically achieved in a spray drying technique. It has been reported in the literature 
that the high air inlet temperature normally causes an excessive evaporation and cracks the 
membrane resulting in high amount of encapsulated ingredients collected [2, 19]. Similarly, 
the drying rate applied in this study produced the higher ratio of surface to volume for the 
spray-dried particles resulting in the lower density of the powders (Table 2) [20]. Calculated 
bulk and tap density results for all spray dried formulations are represented in Table 2. It will 
be interesting to investigate the effect of this low density of the particles on the controlled 
release of the anti-tubercular agent INH. 
Particle size distributions on the basis of volume mean diameter for all spray dried 
formulations were narrow and monomodal with low span values. The calculated span values 
were between 1.1 and 1.2 for S100 systems, between 1.1 to 1.3 for EZE and between 1.0 and 
1.2 for EC10 while the specific surface area (SSA) was in between 68.15-106.90 m
2
/g. The 
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geometric median particle size (d50) of all spray dried particles was in the range of 5.7–6.0 
μm while the d(10) and d(90) stayed between 1.2-1.3 μm and 8.3-9.4 μm, respectively as the 
spray drying process was optimised. The study of the loss on drying (LoD) revealed that a 
minimal amount of moisture or residue solvent was left in the micro-particles after the spray 
drying process. It was observed that only about ~2% (w/w) was lost in the LoD experiments 
making it a suitable processing technology to satisfy the use of organic solvents and 
regulatory requirements. 
 
 
3.2 Particle morphology and surface analysis 
The micrographs of INH loaded formulations revealed spherical shaped particles (Fig. 
2a). No drug crystals were seen on the surface of the spray dried micro-nano particles even at 
relatively high magnifications (magnifications up to X 30.0 K). This simply indicates that the 
highly crystalline INH particles have been encapsulated/coated by the amorphous polymers 
and hence the spherical particles seen under the microscope represents mainly the polymer. 
Interestingly, it has been seen that a large number of particles fell in the nano-sized range 
which may prove efficient for developing some drug molecule to overcome solubility issues. 
A further analysis of SEM/EDS undertaken to elucidate the presence and distribution 
of the drug particles in the spray dried polymeric matrices showed a homogenous distribution 
of the drug throughout. From the structural analysis of the drug and the polymers used as 
shown in Fig. 1, only the drug has nitrogen (N) atoms in its structure while both polymers are 
made of mainly O and C. Therefore, an elemental analysis of N atoms in all spray dried 
particles will indicate the homogeneity of the drug distribution. Therefore, for the purpose of 
this study, N atoms were used as a marker to confirm the presence of the drug in the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
13 
 
microencapsulated polymeric matrices. The distribution of the drug was experimented by 
implementing the EDS elemental mapping of N atoms (Fig. 2b). The EDS mapping showed 
that majority of the area was covered by the O and C which was expected as most of the 
organic drugs and polymers are composed of mainly these two atoms, likewise the drug and 
the polymers used in this study. As results of this, in all spray dried particles, the amount of N 
present comprised comparatively the least proportion of all of the other elements.  
As depicted in Fig. 2b, the bulk INH represented a homogenous distribution of the 
marker atoms (N) indicated by the deep blue color in EDS mapping. Any presence of N 
atoms in any of the spray dried formulations would have indicated the presence of the N 
containing drug INH. From Fig. 2b, it is obvious that INH was homogenously distributed in 
the spray dried microcapsules as indicated by the blue color. The image showed that the 
distribution of N atoms in the INH/S100 systems is homogeneous throughout the particle 
captured in the microscope. The data presented from the advanced EDS analysis of INH/S100 
showed  complementing results compared to that of pure INH. The foregoing is supported by 
the literature as well [21, 22]. 
3.3 XRPD studies 
The crystallinity of the drug in the microencapsulated particles was analyzed by X–
ray diffraction.  As can be seen in Fig. 3, the diffractogram of pure INH exhibited major 
distinct intensity peaks at various 2-theta positions ranging from 10 to 30 2θ degrees while 
the polymers (S100 and ECN10) exhibited peaks due to their amorphous nature. However, 
the co-processed Acryl EZE showed some characteristic peaks due to the presence of 
crystalline materials in the structure (data not shown). The spray dried micro-nano particles 
showed identical low intense peak due to the presence of crystalline INH in the formulations. 
The reduction in the intensity of the crystallinity indicated the increase in the amorphicity of 
the drug present in the spray dried powders. Apparently, it has been seen that the increase in 
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the amount of polymers in the formulations resulted in the decrease in the crystallinity for all 
drug/polymer compositions.   
3.4 Thermal analysis 
The solid state of the drug, bulk polymer and the formulations were studied by the 
DSC. Fig. 4a depicts the DSC traces of the pure drug and the polymers. The highly 
crystalline (crystallinity higher than 92%) INH showed a sharp thermal endothermic event at 
172.10
o
C due to its melting with the enthalpy, H = 222.35 J/g. The thermal analysis of the 
bulk polymers showed that unlike S100 and ECN10, EZE exhibited a crystalline thermal 
transitions at about 75
o
C which corresponds to the melting of the crystalline substances 
present in the co-processed polymer. Similar findings have been reported elsewhere [23]. The 
amorphous S100 and ECN10 showed a thermal event at about 165
o
C and 133
o
C, respectively 
corresponding to their glass transitions.  
Fig. 4b shows the detailed thermal events of the spray dried formulations. The 
formulation containing ECN10 as carrier showed significant shifts on both the melting 
transition and the Tg of the polymer. This could be attributed to the possible drug/polymer 
interactions. Interestingly, with the increase in the polymer contents in the formulations, the 
melting point of the drug has been reduced significantly to 139.31 
o
C but the Tg has been 
slightly increased. This is expected as the increased amount of the polymer present in the 
systems have contributed to the increased Tg values. Quite similar results were observed for 
other polymers. The overall findings from the DSC traces can claim that the shifts of the INH 
melting points may have been attributed to the amorphicity increase of the drug as 
complemented by XRPD data or this could also happen due to the solublisation of the drug in 
the polymeric matrices used during the spray drying. The traces corresponding to the melting 
of the drug in the spray dried system were visible at 133.30-164.12
o
C depending on the Tg 
and nature of the polymers.   
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3.5 Surface elemental analysis via XPS 
Advanced application of XPS to outline the first layer atomic structures of the bulk 
drug, polymers and the spray dried particles was implemented based on the hydrogen 
consumption approach. The chemical elemental surveys of the drug, polymer and active 
formulations are depicted in Fig. 5a. It shows that the drug contains about 54% of C while 
17% O and about 34% N. The elemental ratios are in in good agreement with that of 
theoretically calculated values.  In contrast, S100 predominantly contained 75% C while EZE 
contained O, C, Mg and Si as it is a co-processed polymer with crystalline substances and 
silica/Talc.  
The peak fitting and data interpretation using the CasaXPS software determined 
the N (1s) binding energy (BE) at ~399.3 eV and ~402.0 eV corresponding to the two 
different N environments present in the INH structure (Fig. 5b). These two different N atoms 
may contribute to different types of protonation effects. The ratio between the two N 
environments may prove significantly important to determine and possibly outline the 
interactions between the drug and the anionic polymers. 
The N (1s) BE values of ~402.0 eV in INH indicates the protonation effects of the 
NH
+
 group. Interestingly, this has been shifted to ~402.7 eV in S100 system and ~402.9 eV 
for EZE (Fig. 5b). Apparently, these significant shifts in the BE values of N atoms are 
attributed to the interactions of the drug and the respective polymers. These also are due to 
the heavy protonation effect of N atoms in the spray dried particles resulting in the interaction 
via the amide group of the drug and the carboxyl group of the polymers [24-26]. The 
calculated low N coefficient values in the formulations revealed that the interactions between 
the drug and polymers are quite strong. It has been reported that the lower N coefficient value 
leads to a high number of protonated N atoms that take part in the interactions making it 
stronger [27-30].
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3.6 In vitro dissolution studies 
The main aim of this study was to evaluate the drug release behavior of the 
manufactured spray dried microencapsulated particles as INH is highly water soluble drug the 
release rate is very fast  (>80% release in 1 h) [31].  The in vitro dissolution results are shown 
in Figures 6a and 6b. The drug/polymer ratio of 1:1 with three different polymers showed a 
different controlled release pattern for the first 2 h and then a burst release when the pH was 
increased to 6.8 (Fig. 6a). This could highly be attributed to the pH dependent dissolution of 
anionic S100 and EZE polymers. It has been reported that none of these polymers dissolved 
at pH below 6-6.5 [32]. In contrast, when ECN10 was used as the polymeric carrier, a 
relatively faster drug release was observed due to the pH independent dissolution of the 
polymer.  
 Interestingly, when the polymer content was increased in the formulations (drug: 
polymer ratio 1:3), the drug release seemed to reduce (Fig. 6b) due to the increased amount of 
the release retarding polymers which played a pivotal role to slow down the release of the 
highly soluble drug. Formulations containing S100, generally, showed a very slow release 
profile throughout the study for 12 h while for EZE, a faster release was observed when the 
pH was increased from 1.2 to 6.8 after 2 h. This could be due to the co-processed nature of 
the polymer and a bit lower pH dependency. Regardless of the formulation compositions, the 
release of the drug from all spray dried particles were controlled which proves the effective 
role of these polymers to develop controlled release formulations via spray dried 
encapsulation technique. ANOVA statistical test showed that for the same polymer the ratio 
of drug: polymer ratios have no significant effects on the drug release (p>0.05). 
3.7 Release mechanism studies  
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The kinetic parameters derived from the various release kinetic models of the INH 
release are summarized in Table 3. The analysis of the correlation coefficient (R
2
) in all 
models used indicated that the maximum R
2 
was found in the First Order release kinetics 
model. Therefeore, analyses performed by DDSolver software revealed that the drug release 
mechanism followed a first order release kinetics (Table 3) for all of the formulations 
prepared.  
 
4. Conclusions 
A spray drying process was successfully implemented for the microencapsulation of 
isoniazid which proved a promising approach to develop controlled release dosage forms. 
The microscopic investigation showed that the obtained micro-particles were spherical in 
shape and a mean particle size less than 10 microns. The solid state analysis revealed the 
existence of the semi crystalline INH in the polymer matrices. The advanced surface analysis 
conducted by using EDS showed a homogeneous distribution of the drug in the polymeric 
spray dried particles while the first layer elemental analysis via XPS revealed a strong 
intermolecular interaction between the drug and the polymer used in all formulations. In 
addition, the manufactured particles showed a controlled (pH dependent) release of the 
soluble INH which proves that this emerging processing technology can successfully be 
implemented to develop modified release solid dosage forms. 
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TABLES 
 Table 1. Parameters for spray drying of INH loaded microparticles with B-290, drug loading 
(DL) and encapsulation efficiency (EE).  
*DL=Drug loading; EE= Encapsulation efficiency 
 Formulations Inlet 
Temp          
(
0
C) 
Aspirator Feed 
flow 
(%) 
Pressure 
(mbar) 
Yield 
(%) 
DL* 
(%) 
EE* 
(%) 
F1 INH/S100 (1:1) 100 90 13 25 67 40.6 81.2 
F2 INH/S100  (1:3) 100 90 13 25 64 22.8 91.2 
F3 INH/EZE (1:1) 100 90 15 20 63 40.5 81.0 
F4 INH/EZE (1:3) 100 90 15 20 64 23.6 94.4 
F5 INH/EC10 (1:1) 100 90 13 35 72 45.1 90.2 
F6 INH/EC10 (1:3) 100 90 13 35 82 22.8 91.2 
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Table 2: Particle morphology and characteristics of various spray dried controlled release 
particles.  
 F1 F2 F3 F4 F5 F6 
d10  (μm) 1.2±0.02 1.2±0.01 1.3±0.00 1.3±0.00 1.3±0.04 1.3±0.00 
d50  (μm) 5.7±0.01 5.7±0.01 5.9±0.01 5.9±0.00 6.0±0.01 6.0 ±0.00 
d90 (μm) 8.9±0.04 9.1±0.02 9.4±0.01 8.3±0.01 8.4±0.16 8.2±0.01 
<1 (μm) 8.2±0.71 9.0±0.20 7.7±0.20 9.4±0.01 8.0±0.8 7.8±0.02 
SSA (m
2
/g) 68.15±0.50 75.80±0.10 96.30±0.20 106.90±0.07 91.50±0.01 95.40±0.05 
Bulk density 
(g/cm
3
) 
0.15±0.01 0.15±0.01 0.16±0.01 0.14±0.00 0.13±0.01 0.15±0.00 
Tapped density 
(g/cm
3
) 
0.23±0.01 0.25±0.05 0.26±0.02 0.23±0.03 0.22±0.01 0.28±0.02 
LoD 2.21±0.15 1.80±0.20 2.15±0.20 1.25±0.15 2.13±0.15 2.26±0.10 
 
 
 
 
Table 3: Summary of release mechanism of INH from various formulations 
Model Parameter F1 F2 F3 F4 F5 F6 INH 
Zero-order K0 8.86 6.15 10.53 10.38 10.93 7.72 12.5 
r
2
 0.81 0.78 0.764 0.807 0.730 0.630 0.546 
First-order K1 0.24 0.12 0.40 0.32 0.61 0.30 1.72 
r
2
 0.937 0.874 0.958 0.943 0.982 0.847 0.999 
Higuchi Kh 26.69 19.62 32.74 31.28 35.32 25.70 42.55 
r
2
 0.902 0.935 0.893 0.899 0.905 0.835 0.778 
Korsmeyer-Peppas Kkp 21.43 28.24 32.51 25.01 51.37 45.74 76.97 
n 0.62 0.29 0.51 0.62 0.29 0.15 0.33 
Hixson-Crowell KHc 0.07 0.033 0.107 0.094 0.120 0.088 0.13 
r
2
 0.940 0.843 0.961 0.950 0.952 0.834 0.821 
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Figures caption list: 
Figure 1 Chemical structures of the drug and the polymers used. 
Figure 2a SEM images of the encapsulated spray dried INH loaded micro-
particles. 
Figure 2b EDS mapping of bulk INH and the INH/S100 formulations.  
Figure 3 XRPD diffractograms of bulk INH and the spray dried formulations. 
Figure 4a DSC thermal transitions of bulk drug and the polymers. 
Figure 4b DSC traces of the spray dried INH loaded micropartciles. 
Figure 5a Chemical elemental surveys conducted via XPS using CasaXPS 
software. 
Figure 5b Peak fitting of N (1s) binding energy of the drug and the spray dried 
particles with S100 and EZE polymers. 
Figure 6 In vitro dissolution studies of INH pure and the spray dried 
micropartciles at (a) drug/polymer 1:1 ratio and (b) drug/polymer 1:3 
ratio (n=3). 
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Fig. 2a  
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Fig. 2b  
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Fig. 3  
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Fig. 4a  
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Fig. 4b  
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Fig. 5a  
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Fig. 5b  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
32 
 
 
 
Fig. 6  
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Highlights: 
 The surface chemistry plays a pivotal role in micro-encapsulations 
 Suitable polymers are important to manufacture controlled release micro-particles 
 EDX analyses the drug distribution on the particle surface  
 XPS outlines a possible interaction pattern between the drug and carriers  
 Optimised process and formulations control release of highly soluble drug   
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